(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 17.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Harmony Biosciences Holdings's revenue in 2024 is $582,022,000.On average, 3 Wall Street analysts forecast HRMY's revenue for 2024 to be $40,424,865,197, with the lowest HRMY revenue forecast at $39,759,928,951, and the highest HRMY revenue forecast at $40,828,323,055. On average, 2 Wall Street analysts forecast HRMY's revenue for 2025 to be $47,399,344,181, with the lowest HRMY revenue forecast at $46,982,091,436, and the highest HRMY revenue forecast at $47,816,596,926.
In 2026, HRMY is forecast to generate $52,829,306,779 in revenue, with the lowest revenue forecast at $51,739,340,423 and the highest revenue forecast at $53,919,273,134.